Destiny Pharma Overview
- Year Founded
-
1997
- Status
-
Out of Business
- Employees
-
15
- Latest Deal Type
-
Liquidation
- Financing Rounds
-
10
Destiny Pharma General Information
Description
Developer of antimicrobial drugs focused on the development of medicines for the treatment of infectious diseases. The company offers XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for the prevention of post-surgical staphylococcal infection, and NTCD-M3, among others.
Contact Information
Website
www.destinypharma.comCorporate Office
- Sussex Innovation Centre, Science Park Square
- Falmer
- Brighton BN1 9SB
- England, United Kingdom
Corporate Office
- Sussex Innovation Centre, Science Park Square
- Falmer
- Brighton BN1 9SB
- England, United Kingdom
Destiny Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Destiny Pharma Comparisons
Industry
Financing
Details
Destiny Pharma Competitors (36)
One of Destiny Pharma’s 36 competitors is Ardelyx, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ardelyx | Formerly VC-backed | Waltham, MA | ||||
| BioMarin Pharmaceutical | Formerly PE-Backed | San Rafael, CA | ||||
| Spero Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Scynexis | Formerly VC-backed | Jersey City, NJ | ||||
| LEO Pharma | Private Equity-Backed | Ballerup, Denmark |
Destiny Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Destiny Pharma Patents
Destiny Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022180380-A1 | Combination of mupirocin with porphyrin-based photosensitizers for reducing antibiotic resistance emergence | Inactive | 23-Feb-2021 | ||
| GB-202102556-D0 | Method for reducing antibiotic resistance emergence | Inactive | 23-Feb-2021 | ||
| AU-2009306132-A1 | Novel uses | Inactive | 24-Oct-2008 | ||
| EP-2355816-A2 | Novel uses | Active | 24-Oct-2008 | ||
| WO-2010046663-A2 | Novel uses | Inactive | 24-Oct-2008 | C07D487/22 |
Destiny Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Destiny Pharma FAQs
-
When was Destiny Pharma founded?
Destiny Pharma was founded in 1997.
-
Where is Destiny Pharma headquartered?
Destiny Pharma is headquartered in Brighton, United Kingdom.
-
What is the size of Destiny Pharma?
Destiny Pharma has 15 total employees.
-
What industry is Destiny Pharma in?
Destiny Pharma’s primary industry is Drug Discovery.
-
Is Destiny Pharma a private or public company?
Destiny Pharma is a Private company.
-
What is Destiny Pharma’s current revenue?
The current revenue for Destiny Pharma is .
-
How much funding has Destiny Pharma raised over time?
Destiny Pharma has raised $72.5M.
-
Who are Destiny Pharma’s competitors?
Ardelyx, BioMarin Pharmaceutical, Spero Therapeutics, Scynexis, and LEO Pharma are some of the 36 competitors of Destiny Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
